[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100373296":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":42,"responsibleParty":57,"collaborators":18,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":18,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":82,"overallStatus":45,"whyStopped":18,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Antibiotic","EXPERIMENTAL","Participate will be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration",[13],"Drug: Ertapenem",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","Participate will not be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Ertapenem","inject from iv drip before endoscopic cyanoacrylateinjection obliteration",[9],[26],"Invanz",[28],{"name":29,"affiliation":5,"role":30},"Ming-Chih Hou","PRINCIPAL_INVESTIGATOR",[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Ming-Chih Hou, MD","CONTACT","886-2-28712111","7877","mchou@vghtpe.gov.tw",{"name":39,"role":34,"phone":35,"phoneExt":40,"email":41},"Pei-Chang Lee, MD","3972","pclee7@vghtpe.gov.tw",[43],{"facility":44,"status":45,"city":46,"state":18,"zip":18,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Veteran General Hospital-Taipei","RECRUITING","Taipei","Taiwan","TW",{"type":50,"coordinates":51},"Point",[52,53],121.52639,25.05306,{"lat":53,"lon":52},[56],{"name":29,"role":34,"phone":18,"phoneExt":18,"email":18},{"type":58,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100373296","phase-4-antibiotic-prophylaxis-in-patients-undergoing-gvo-100373296",false,"NCT04140578","Antibiotic Prophylaxis in Patients Undergoing GVO","Antibiotic Prophylaxis in Patients Undergoing Endoscopic Injection of Cyanoacrylate for Primary and Secondary Prevention of Gastric Variceal Bleeding","ABX-GV","Inclusion Criteria:\n\n1. Patients with live cirrhosis and\u002For hepatoma\n2. Aged 20 to 85, who had endoscopy-treatment EV(-)GV(+)or EV\\\u003CGV\n\nExclusion Criteria:\n\n1. Had a terminal illness of any major organ system,such as heart failure, kindey failure,COPD\n2. Patients recieve antibiotics recently.\n3. Patients suspected infection.","ALL","20 Years","85 Years",{"count":71,"type":72},150,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","We design a randomized trial to clarify the necessity of antibiotic prophylaxis for the patients chronic liver disease with gastric varices treated by elective GVO.",[78,79,80,81],"Gastric Varix","Sepsis","Liver Cirrhoses","Fever",[83,79,84],"Gastric variceal rebleeding","cyanoacrylate injection","2019-10-24",{"date":87,"type":88},"2019-10-28","ACTUAL",{"date":90,"type":88},"2017-01-28",{"date":92,"type":72},"2030-12-31",{"name":5,"class":6},1]